Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23579911 | 0.84 | CYP3A4 (0.51) | ALDH1A1CYP3A4TDP1LMNARAB9A | |
| SCHEMBL23580754 | 0.83 | TDP1 (0.53) | ALDH1A1CYP3A4TDP1LMNATSHR | |
| SCHEMBL29972976 | 0.82 | PTGS2 (0.44) | ALDH1A1CYP3A4TDP1LMNARAB9A | |
| SCHEMBL8889748 | 0.82 | TDP1 (0.51) | ALDH1A1CYP3A4TDP1RAB9AMAPT | |
| SCHEMBL1457013 | 0.82 | ALDH1A1 (0.50) | ALDH1A1CYP3A4TDP1LMNATSHR | |
| SCHEMBL16586317 | 0.81 | TDP1 (0.55) | ALDH1A1TDP1LMNATSHRRAB9A | |
| SCHEMBL11670038 | 0.80 | ALDH1A1 (0.53) | ALDH1A1TDP1LMNATSHRRAB9A | |
| SCHEMBL29105509 | 0.80 | TDP1 (0.53) | ALDH1A1TDP1LMNATSHRRAB9A | |
| SCHEMBL30645294 | 0.80 | ALDH1A1 (0.53) | ALDH1A1TDP1LMNATSHRRAB9A | |
| SCHEMBL11671011 | 0.80 | CRHBP (0.62) | ALDH1A1TDP1TSHRRAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339150-B2 | Benzimidazole compounds as HDAC6 inhibitors | ONKURE, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20220041584-A1 | BENZIMIDAZOLE COMPOUNDS AS HDAC6 INHIBITORS | ONKURE, INC. (US) | 2022-02-10 | — | — | US | disclosed |
| WO-2021133957-A1 | BENZIMIDAZOLE COMPOUNDS AS HDAC6 INHIBITORS | ONKURE, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| EP-2041118-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007114827-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007114827-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20060247263-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2006-11-02 | — | — | US | disclosed |
| EP-1172356-B1 | Process for producing N-acylnitroaniline derivative | SUMITOMO CHEMICAL CO (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-6630598-B2 | Reacting nitroaniline compound with acid chloride/anhydride in presence of alkali metal/earth metal compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-10-07 | — | — | US | disclosed |
| US-20030181730-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-09-25 | — | — | US | disclosed |
| US-6495583-B1 | DRUG FOR TREATING AN ALPHA-2 ADRENERGIC RECEPTOR ASSOCIATED DISORDER, NASAL CONGENSTION AND ALLEVIATING PAIN | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-12-17 | — | — | US | disclosed |
| US-6436982-B1 | USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-08-20 | — | — | US | disclosed |
| US-20020072536-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-06-13 | — | — | US | disclosed |
| US-6403626-B1 | USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-06-11 | — | — | US | disclosed |
| US-20020065307-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-05-30 | — | — | US | disclosed |
| US-20020016506-A1 | Process for producing N-acylnitroaniline derivative | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-02-07 | — | — | US | disclosed |
| EP-1172356-A1 | Process for producing N-acylnitroaniline derivative | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-01-16 | — | — | EP | disclosed |
| EP-0775134-A4 | NOVEL BENZIMIDAZOLE DERIVATIVES | SYNAPTIC PHARMA CORP (US) | 1997-08-13 | — | — | EP | disclosed |
| EP-0775134-A1 | Imidazolin-2-ylaminobenzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004270-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041584-A1 | BENZIMIDAZOLE COMPOUNDS AS HDAC6 INHIBITORS | HDAC6, HDAC1, HDAC11 | ALDH1A1 285/4885CYP3A4 2771/4885TDP1 1174/4885 |
| US-20020065307-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | ALDH1A1 938/4885CYP3A4 167/4885TDP1 3735/4885 |
| US-20020072536-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | ALDH1A1 923/4885CYP3A4 159/4885TDP1 3722/4885 |
| US-20020016506-A1 | Process for producing N-acylnitroaniline derivative | NAAA, NAT1, ACOT7 | ALDH1A1 824/4885CYP3A4 602/4885TDP1 3946/4885 |
| US-11339150-B2 | Benzimidazole compounds as HDAC6 inhibitors | HDAC6, HDAC1, HDAC11 | ALDH1A1 285/4885CYP3A4 2771/4885TDP1 1174/4885 |
| US-20060247263-A1 | Substituted heterocyclic compounds and methods of use | MAPT, IAPP, MYLK2 | ALDH1A1 2737/4885CYP3A4 1141/4885TDP1 1915/4885 |
| US-20030181730-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | ALDH1A1 938/4885CYP3A4 167/4885TDP1 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.